BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 580058)

  • 1. [Azapropazone plasma levels under simultaneous treatment with an antacid or laxative].
    Faust-Tinnefeldt G; Geissler HE; Mutschler E
    Arzneimittelforschung; 1977; 27(12):2411-4. PubMed ID: 580058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [On the determination of azapropazone from plasma by direct quantitative thin-layer chromatography (author's transl)].
    Geissler HE; Mutschler E; Faust-Tinnefeldt G
    Arzneimittelforschung; 1977; 27(9):1713-5. PubMed ID: 579143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Kinetics of digitoxin during antirheumatic therapy with azapropazone (author's transl)].
    Faust-Tinnefeldt G; Gilfrich HJ
    Arzneimittelforschung; 1977; 27(10):2009-11. PubMed ID: 579114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Plasma level of azapropazone during its combined administration with digitoxin].
    Faust-Tinnefeldt G; Geissler HE; Gilfrich HJ
    Med Welt; 1979 Feb; 30(5):181-2. PubMed ID: 310503
    [No Abstract]   [Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Azapropazone and rheumatic combination therapy considering drug interactions: azapropazone aurothioglucose and azapropazone prednisolone].
    Faust-Tinnefeldt GF; Geissler HE
    Arzneimittelforschung; 1978; 28(2):337-41. PubMed ID: 346022
    [No Abstract]   [Full Text] [Related]  

  • 7. The determination of azapropazone in blood plasma.
    Leach H
    Curr Med Res Opin; 1976; 4(1):35-43. PubMed ID: 1261300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of azapropazone following single oral and intravenous doses.
    Breuing KH; Gilfrich HJ; Meinertz T; Jähnchen E
    Arzneimittelforschung; 1979; 29(6):971-2. PubMed ID: 582795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Plasma azapropazone level during combination therapy of rheumatoid diseases].
    Faust-Tinnefeldt G; Geissler HE; Gilfrich HJ
    Verh Dtsch Ges Inn Med; 1978; (84):1502-5. PubMed ID: 311119
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of antacid on the bioavailabiity of lithium carbonate.
    Goode DL; Newton DW; Ueda CT; Wilson JE; Wulf BG; Kafonek D
    Clin Pharm; 1984; 3(3):284-7. PubMed ID: 6428800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Azapropazone plasma levels in rheumatologic therapy with D-penicillamine combined with immunosuppressive agents].
    Faust-Tinnefeldt G; Geissler HE; Mutschler E
    Arzneimittelforschung; 1977; 27(11):2153-7. PubMed ID: 580020
    [No Abstract]   [Full Text] [Related]  

  • 12. [Determination of azapropazone and 8-hydroxyazapropazone in urine by direct quantitative thin-layer chromatography (author's transl)].
    Geissler HE; Faust-Tinnefeldt G; Mutschler E
    Arzneimittelforschung; 1978; 28(8):1430-1. PubMed ID: 582413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma protein binding of azapropazone in patients with kidney and liver disease.
    Jähnchen E; Blanck KJ; Breuing KH; Gilfrich HJ; Meinertz T; Trenk D
    Br J Clin Pharmacol; 1981 Apr; 11(4):361-7. PubMed ID: 7259929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent NSAID.
    Dittrich P; Radhofer-Welte S; Magometschnigg D; Kukovetz WR; Mayerhofer S; Ferber HP
    Drugs Exp Clin Res; 1990; 16(2):57-62. PubMed ID: 2401187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of antacids on plasma concentration of digoxin in man (author's transl)].
    Vöhringer HF; Kuhlmann J; Rietbrock N
    Dtsch Med Wochenschr; 1976 Jan; 101(4):106-8. PubMed ID: 1245165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics and laxative effect of bisacodyl following administration of various dosage forms].
    Roth W; Beschke K
    Arzneimittelforschung; 1988 Apr; 38(4):570-4. PubMed ID: 3401271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers.
    Krishna G; Kisicki JC; Olsen S; Grasela DM; Wang Z
    Pharmacotherapy; 2007 Jul; 27(7):963-9. PubMed ID: 17594201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentration of azapropazone in synovial tissues and fluid.
    Spahn H; Thabe K; Mutschler E; Tillmann K; Gikalov I
    Eur J Clin Pharmacol; 1987; 32(3):303-7. PubMed ID: 3595703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of acarbose and simultaneous antacid therapy on blood glucose.
    Höpfner M; Durani B; Spengler M; Fölsch UR
    Arzneimittelforschung; 1997 Oct; 47(10):1108-11. PubMed ID: 9368703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopic evaluation of the effect of azapropazone on the gastric mucosa.
    Hradsky M; Bruce L
    Scand J Rheumatol; 1978; 7(1):31-2. PubMed ID: 675173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.